Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

70.46
+0.64000.92%
Volume:397.06K
Turnover:27.62M
Market Cap:5.88B
PE:-115.51
High:70.49
Open:69.67
Low:68.02
Close:69.82
52wk High:90.87
52wk Low:48.28
Shares:83.46M
Float Shares:77.19M
Volume Ratio:0.53
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-35.56
PE(LYR):9.06

Loading ...

PTC Therapeutics is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 01

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Regeneron (REGN) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 31

Werewolf Therapeutics Posts Q2 Profit on Jazz Asset Sale

Reuters
·
Jul 31

PTC Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

PTC Therapeutics Director Hege Elisabeth Sollie-Zetlmayer Files Initial Beneficial Ownership Statement

Reuters
·
Jul 31

PTC Therapeutics Raises Outlook on Strong Q2 Results

TIPRANKS
·
Jul 31

PTC Therapeutics Posts Corporate Presentation Highlighting Sephience PKU Launch Momentum

Reuters
·
Jul 31

GUIDANCE: (PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.18B - $1.28B, vs. FactSet Est of $1.18B

MT Newswires Live
·
Jul 31

Earnings Flash (PTCT) PTC Therapeutics Posts Q2 EPS $0.92, vs. FactSet Est of $0.24

MT Newswires Live
·
Jul 31

PTC Therapeutics Q2 FY26 Net Income Swings to $83.5 Million; Revenue More than Doubles to $361 Million

Reuters
·
Jul 31

PTC Therapeutics Q2 EPS $0.92 Beats $0.23 Estimate, Sales $360.519M Beat $298.963M Estimate

Benzinga Earnings
·
Jul 31

PTC Therapeutics Q2 EPS USD 0.92

THOMSON REUTERS
·
Jul 31

PTC Therapeutics: Total Product Revenue Guidance Raised to $850 to $950 Million for FY 2026

THOMSON REUTERS
·
Jul 31

PTC Therapeutics Q2 Net Income USD 83.496 Million

THOMSON REUTERS
·
Jul 31

PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says

MT Newswires Live
·
Jul 27

Earning Preview: PTC Therapeutics Q2 revenue is expected to increase by 74.33%, and institutional views are mostly bullish

Earnings Agent
·
Jul 24

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director

THOMSON REUTERS
·
Jul 23

Barclays Remains a Buy on PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Personalis (PSNL) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 20

PTC Therapeutics is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 20